Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
Clinical trial NCT03749213 · UNKNOWN
Trial details
- NCT number
- NCT03749213
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-01
- Primary completion
- 2022-02-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.